About ptc therapeutics - PTCT
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
PTCT At a Glance
PTC Therapeutics, Inc.
500 Warren Corporate Center Drive
Warren, New Jersey 07059
| Phone | 1-908-222-7000 | Revenue | 1.73B | |
| Industry | Pharmaceuticals: Major | Net Income | 682.64M | |
| Sector | Health Technology | 2025 Sales Growth | 114.514% | |
| Fiscal Year-end | 12 / 2026 | Employees | 991 | |
| View SEC Filings |
PTCT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 9.764 |
| Price to Sales Ratio | 3.876 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 9.43 |
| Enterprise Value to EBITDA | 5.765 |
| Enterprise Value to Sales | 2.982 |
| Total Debt to Enterprise Value | 0.077 |
PTCT Efficiency
| Revenue/Employee | 1,746,372.351 |
| Income Per Employee | 688,843.592 |
| Receivables Turnover | 9.529 |
| Total Asset Turnover | 0.748 |
PTCT Liquidity
| Current Ratio | 2.348 |
| Quick Ratio | 2.266 |
| Cash Ratio | 2.009 |
PTCT Profitability
| Gross Margin | 95.854 |
| Operating Margin | 49.49 |
| Pretax Margin | 40.252 |
| Net Margin | 39.444 |
| Return on Assets | 29.501 |
| Return on Equity | N/A |
| Return on Total Capital | 352.997 |
| Return on Invested Capital | N/A |
PTCT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 206.168 |
| Total Debt to Total Assets | 13.695 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 49.943 |